

1 **The *Chlamydia* type III effector TarP alters the dynamics and organization of**
2 **host focal adhesions**

3 António T. Pedrosa^{a,b}, Ana T. Nogueira^{a,b}, Tristan R. Thwaites^b, Jesse Aaron^c, Teng-Leong Chew^c,
4 and Rey A. Carabeo^{a,1}

5
6 ^aSchool of Molecular Biosciences, College of Veterinary Medicine, Washington State University,
7 Pullman, WA 99164; ^bBacteriology Section, Programme in Microbiology, Institute of Medical
8 Sciences, University of Aberdeen, Aberdeen, UK AB25 2ZD; ^cAdvanced Imaging Center, Janelia
9 Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Corresponding author:

Rey A. Carabeo

School of Molecular Biosciences

College of Veterinary Medicine

Washington State University

Pullman, WA 99164

(509) 335-7788

Mail to: rcarabeo@vetmed.wsu.edu

Keywords: *Chlamydia*, Focal adhesion, Pathogenesis, FA modulation, Adhesion, iPALM

25 **Abstract**

26 Bacterial infection of mucosal epithelial cells triggers cell exfoliation to limit the dissemination of
27 infection within the tissue. Therefore, mucosal pathogens must possess strategies to counteract cell
28 extrusion in response to infection. *Chlamydia trachomatis* spends most of its intracellular
29 development in the non-infectious form. Thus, premature host cell extrusion is detrimental to the
30 pathogen. We demonstrate that *C. trachomatis* alters the dynamics of focal adhesions. Live-cell
31 microscopy showed that focal adhesions in *C. trachomatis*-infected cells displayed increased
32 stability. In contrast, focal adhesions in mock-infected cells readily disassembled upon inhibition of
33 myosin II by blebbistatin. Super-resolution microscopy revealed a reorganization of paxillin and FAK
34 in infected cells. Ectopically expressed type III effector TarP localized to focal adhesions, leading to
35 their stabilization and reorganization in a vinculin-dependent manner. Overall, the results indicate
36 that *C. trachomatis* possesses a dedicated mechanism to regulate host cell focal adhesion
37 dynamics.

38

39 Introduction

40 Bacterial infection of mucosal epithelial cells triggers the antimicrobial defence strategy of cell
41 exfoliation and apoptosis induction (reviewed in: Kim *et al.*, 2010). The controlled extrusion of
42 damaged host cells and colonizing pathogens requires the degradation of cell adhesion factors.

43 In epithelial cells, focal adhesions and hemidesmosomes are primarily responsible for attachment to
44 the extracellular matrix, and their assembly and turnover are exquisitely regulated at multiple levels,
45 by kinases, phosphatases, protein-protein interactions, internalization of components, and
46 degradation (Borradori and Sonnenberg, 1999; Geiger *et al.*, 2001; Zaidel-Bar *et al.*, 2007).
47 Disruption of one or more of these regulatory processes alters the adhesion dynamics and
48 properties of the cells.

49 One strategy employed by bacteria to neutralize exfoliation relies on the precise targeting of
50 one or more component of the focal adhesion proteome. The best-characterized example is that of
51 *Shigella*, which neutralizes epithelial extrusion to colonize the epithelium efficiently. It does so by
52 delivering the OspE effector by the type III secretion system (T3SS). This protein reinforces host
53 cell adherence to the basement membrane by interacting with integrin-linked kinase (ILK), a
54 serine/threonine kinase that is part of the focal adhesome (Zaidel-Bar *et al.*, 2007). A consequence
55 of the OspE-ILK interaction is an increased surface expression of β 1-integrin, which in turn
56 promotes focal adhesion (FA) assembly. In addition, the OspE-ILK complex stabilizes the focal
57 adhesions (FAs) by reducing phosphorylation of focal adhesion kinase (FAK) at a functionally
58 important Tyr397 residue and of paxillin. Inhibition of both phosphorylation events has been shown
59 to induce FA disassembly (Kim *et al.*, 2009). Interestingly, some EPEC and EHEC strains, as well
60 as *Citrobacter rodentium* possess the effector EspO, which shares strong homology with OspE
61 (reviewed in Vossenkämper, Macdonald and Marchès, 2011; Morita-Ishihara *et al.*, 2013). As such,
62 it is conceivable that these pathogens also reinforce adherence of the infected epithelial cells to
63 secure an infectious foothold. The EspZ effector of EPEC and EHEC has been shown to reduce cell
64 death and detachment *in vitro* (Shames *et al.*, 2010). EspZ binds the transmembrane glycoprotein
65 CD98 and enhances its effect on β 1-integrin signalling and cell survival via activation of
66 FAK(Shames *et al.*, 2010).It is possible that EspO and EspZ may cooperate to confer enhanced

67 adhesion of the host epithelial cells to the extracellular matrix. Finally, through interaction with
68 human carcino-embryonic antigen-related cell adhesion molecules (CEACAM), bacterial pathogens
69 such as *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Moraxella catarrhalis*, and *Haemophilus*
70 *influenzae* can activate β 1-integrin signalling and inhibit epithelial cell detachment (reviewed in: Kim
71 *et al.*, 2010). Despite numerous examples of pathogens manipulating host cell adhesion, the details
72 of the mechanisms remain uncharacterized.

73 Chlamydiae are obligate intracellular pathogens that are distinguished by their biphasic
74 developmental cycle that alters between the infectious elementary body (EB), and the replicative,
75 but non-infectious reticulate body (RB). At late time points, the non-infectious RBs convert back to
76 EBs to produce infectious particles for the next round of infection. The entire intracellular growth
77 cycle of *Chlamydia* takes ~48–96 h and occurs within a membrane-bound inclusion, and most of it
78 is spent in the non-infectious RB form. Thus, it is essential that the adhesion of the infected cells to
79 the epithelium is sustained during chlamydial development to enable the differentiation of the non-
80 infectious RBs to the infectious and stable elementary bodies (EBs) (reviewed in AbdelRahman and
81 Belland, 2005). This means that *Chlamydia* must evade a host of antimicrobial defences, including
82 epithelial extrusion.

83 Previous works by Kumar and Valdivia (2008) and Heymann *et al.*, (2013) described the
84 loss of motility of *Chlamydia*-infected epithelial cells. Heymann *et al.*, (2013) attributed this to the
85 chlamydial inhibition of Golgi polarization that occurs at >24 h post-infection, leading to loss of
86 directional migration. In this report, we offer an alternate and possibly complementary mechanism of
87 FA stabilization, which could lead to an increase of host-cell adhesion to the extracellular matrix
88 (ECM), thus culminating in loss of motility as previously described (Kumar and Valdivia, 2008;
89 Heymann *et al.*, 2013). Using quantitative confocal and live-cell imaging and super-resolution
90 microscopy, we describe the various aspects of chlamydial modulation of FAs, such as increased
91 number, enhanced stability, and reorganization, which is initiated at early time points and
92 maintained throughout infection. Importantly, we demonstrate a previously unreported post-invasion
93 role for the T3SS effector TarP in influencing these properties. Focal adhesions in *Chlamydia*-
94 infected or TarP-expressing cells displayed unusual resistance to disassembly induced by treatment

95 with blebbistatin, a specific inhibitor of myosin II. In addition, the vertical organizations of the FA-
96 associated proteins, paxillin and FAK were significantly altered in both infected and TarP-
97 expressing cells, indicating a crucial role for the T3SS effector. Furthermore, the FA-stablizing role
98 of TarP was dependent on vinculin, which was confirmed by the inability of TarP with deleted
99 vinculin-binding sites to inhibit FA turnover. Overall, the results indicate that *Chlamydia* has a
100 dedicated mechanism of inhibiting epithelial cell extrusion during its intracellular development.

101 **Results**

102 *Infected cells exhibited increased resistance to detachment*

103 To be able to establish infection in mucosal epithelium *C. trachomatis* needs to overcome the
104 extrusion defence mechanism of the epithelial cells. A mild trypsin treatment was used to determine
105 if *C. trachomatis* serovar L2 (Ctrl2) affected host cell adhesion. Mock- and Ctrl2-infected cells
106 were treated with 0.01% trypsin and fixed with 4% PFA at predetermined time points up to 35 min
107 post-trypsin treatment (Figure 1). A qualitative difference between the infected sample (bottom
108 panel Figure 1A), and mock-infected sample (top panel Figure 1A) was apparent within 10 min of
109 trypsin treatment. The infected cell monolayer of the Ctrl2-infected cells was unaltered up to 30 min
110 after trypsin treatment. In contrast, the mock-infected monolayer developed gaps starting at 10 min
111 of trypsinisation with almost complete loss of cells at 35 min. The number of nuclei in images
112 corresponding to two independent experiments was quantified using the FIJI software (Figure 1B).
113 Data are represented as box-and-whisker plots. The number of nuclei was normalized to the
114 average number of nuclei at 0 min of treatment for each sample. A significant decrease in number
115 of nuclei in the mock-infected sample was observed starting at 10 min post-trypsinization.
116 Alternatively, only a marginal difference was observed in the Ctrl2-infected sample at the 35min
117 time point. Furthermore, a significant difference between the mock- and Ctrl2-infected samples was
118 observed at 10 min post-trypsin treatment, and was maintained for the length of the experiment.
119 Resistance to trypsinization was also observed in cells seeded at low confluence (Movie S1). These
120 results suggested that *Chlamydia* conferred resistance to detachment by trypsinization, possibly by
121 enhancing the adhesion of the host cell to the substrate.

122

123 *Infected cells exhibited focal adhesion changes*

124 The enhanced adhesion of infected cells observed could be due to changes in the number and size
125 of focal adhesions. Focal adhesions are important integrin-based structures that anchor the cell to
126 the ECM. Three different FAs markers were used to monitor the number and turnover dynamics.
127 Cells were either mock- or Ctrl2-infected and then fixed at 8 and 20 h post-infection (hpi). Samples
128 were then stained for paxillin, vinculin, or FAK phosphorylated at Tyr397 (pFAK-Y³⁹⁷) (Figure 2A,

129 2B and S1A). FIJI image software was used to quantify the number of FAs in images obtained by
130 confocal microscopy, and data represented as box-and-whisker plots (Figure 2C, 2D and S1B). In
131 mock-infected cells stained for vinculin, an average number of 34 ± 16 (n=46) FAs were observed.
132 This was significantly lower than vinculin-marked FAs in CtrlL2-infected cells at both 8 and 20 hpi
133 [79 ± 63 (n=45, p-value ≤ 0.001 ; Wilcoxon rank sum test) and 75 ± 36 (n=45, p-value ≤ 0.001 ;
134 Wilcoxon rank sum test), respectively]. Similarly, a significant increase in FA numbers was
135 observed at 20 hpi between mock- and CtrlL2-infected cells for FAs marked with paxillin [32 ± 11
136 (n=34) vs. 59 ± 28 (n=18, p-value ≤ 0.001 ; Wilcoxon rank sum test), respectively]. The same
137 significant increase in CtrlL2-infected cells was observed for pFAK-Y³⁹⁷-marked FAs [56 ± 22 (n=40)
138 vs 75 ± 36 (n=45, p-value ≤ 0.001 ; Wilcoxon rank sum test), respectively]. A similar trend was
139 observed at an earlier time point of infection (8 hpi) for paxillin between mock- and CtrlL2-infected
140 cells [32 ± 11 (n=34) vs. 59 ± 27 (n=24, p-value ≤ 0.001 ; Wilcoxon rank sum test), respectively] and
141 pFAK-Y³⁹⁷ [56 ± 22 (n=40) vs. 88 ± 49 (n=26, p-value ≤ 0.001 ; Wilcoxon rank sum test),
142 respectively]. No significant difference was observed between the CtrlL2 8 hpi and the CtrlL2 20 hpi
143 time points, for the markers mentioned above. Further studies using the focal adhesion marker
144 vinculin revealed that FA numbers significantly increased as early as 2 hpi [$(34 \pm 16$ (n=46) vs. $68 \pm$
145 46 (n=43, p-value ≤ 0.001 ; Wilcoxon rank sum test)] (Figure S1C and S1D).

146 The relatively early time point (2 hpi) of FA modulation by CtrlL2 indicated that a pre-
147 synthesized protein, possibly a T3SS effector associated with elementary bodies might be involved.
148 To test this hypothesis CtrlL2 infection was performed in the presence of chloramphenicol to inhibit
149 *de novo* protein synthesis, yet allowing translocation of pre-synthesized proteins in the EB. For this
150 experiment vinculin and paxillin were used as FA markers (Figure 2A and 2B, respectively). Images
151 obtained by confocal microscopy were quantified using FIJI image software, and data was
152 represented using box-and-whisker plots (Figure 2C and 2D). The results obtained were
153 comparable with the non-chloramphenicol-treated samples. At 8 hpi, significant increase in FA
154 numbers between mock- and CtrlL2-infected cells was observed for vinculin- [34 ± 16 (n=46) vs. 62
155 ± 28 , (n=35, p-value ≤ 0.001 ; Wilcoxon rank sum test), respectively] and paxillin-stained samples
156 [32 ± 11 (n=34) vs. 76 ± 40 , (n=41, p-value ≤ 0.001 ; Wilcoxon rank sum test) , respectively]. A

157 similar significant increase in vinculin- [34 ± 16 (n=46) vs. 76 ± 40, (n=41, p-value ≤ 0.001; Wilcoxon
158 rank sum test), respectively] and paxillin-stained (32 ± 11 (n=34) vs. 49 ± 24 (n=40, p-value ≤ 0.001;
159 Wilcoxon rank sum test) , respectively] FA numbers was observed at 20 hpi. Remarkably,
160 chloramphenicol treatment did not affect the FA numbers of CtrlL2-infected cells, indicating that the
161 protein(s) responsible for changes to focal adhesions at 8 and 20 hpi was already present in EBs.
162 Additionally, inoculation with heat-killed CtrlL2 EBs did not increase FA numbers (Figure S1C and
163 S1D) at 8 and 20 hpi.

164 Focal adhesion modulation was neither *Chlamydia* species nor host cell type-dependent. A
165 qualitative increase in FAs was also observed in HaCaT and MEFs cell lines infected with CtrlL2 for
166 20 h (Figure S2A-S2D). An increase in FAs marked with pFAK-Y³⁹⁷ was also observed in Cos7 cells
167 infected with *Chlamydia caviae* at 8 hpi (Figure S1E and S1F). These results suggested that FA
168 modulation might be conserved in the genus Chlamydia, which would be consistent with this feature
169 being an important adaptive mechanism to infection of the high-turnover mucosal epithelia.

170

171 *Focal adhesion changes in infected cells are associated with increased stability*

172 Focal adhesion numbers are influenced by the dynamics of biogenesis and turnover (Nagano *et al.*,
173 2012; Kim and Wirtz, 2013). We investigated the rates of recruitment and turnover of three FA
174 markers (transiently transfected paxillin-EGFP, FAK-EGFP or vinculin-Venus) in CtrlL2- or mock-
175 infected NIH3T3 cells seeded on fibronectin using quantitative live-cell TIRF microscopy (Movies
176 S2-S4). Individual FAs from time-lapse imaging were analyzed using the Focal Adhesion Analysis
177 Server (FAAS) (Berginski and Gomez, 2013) (Figures 3A, 3B, 3C). With images from each frame
178 indicated by a different colour, the difference in the turnover and spatial dynamics of FAs marked by
179 paxillin-EGFP between CtrlL2 and mock-infected cells was observed (Figure 3A). The same was
180 observed for FAK-EGFP- and vinculin-Venus-labelled FAs (Figure S2E). Figures 3B and 3C
181 illustrate the differences in the recruitment and turnover rates for over 3000 FAs analyzed per
182 condition (data represented using box-and-whisker plots). We observed slower turnover rates for
183 FAs of CtrlL2-infected cells when compared to the mock-infected samples. The average turnover
184 rate for FAK-EGFP in mock-infected cells was 0.047 ± 0.050 intensity/min (n=799) vs. CtrlL2-

185 infected cells 0.031 ± 0.035 intensity/min (n=761) (p-value ≤ 0.001 , Wilcoxon rank sum test). For
186 paxillin-EGFP, the turnover rates for mock-infected and CtrlL2-infected cells were 0.045 ± 0.046
187 intensity/min (n=593) vs. 0.035 ± 0.041 intensity/min (n=750) (p-value ≤ 0.001 , Wilcoxon rank sum
188 test), respectively. Finally, the turnover rate of vinculin-Venus for mock-infected cells was $0.030 \pm$
189 0.030 intensity/min (n=955), while that for CtrlL2-infected cells was 0.024 ± 0.023 intensity/min
190 (n=1113) (p-value ≤ 0.001 , Wilcoxon rank sum test). Interestingly, the rates of recruitment for the
191 same FA markers in CtrlL2-infected cells were slower than those of mock-infected controls. For
192 FAK-EGFP, mock- vs. CtrlL2-infected samples had turnover rates of 0.048 ± 0.040 intensity/min
193 (n=656) and 0.038 ± 0.030 intensity/min (n=584) (p-value ≤ 0.001 , Wilcoxon rank sum test),
194 respectively. Paxillin-EGFP yielded rates of 0.055 ± 0.048 intensity/min (n=644) and 0.035 ± 0.035
195 intensity/min (n=773) (p-value ≤ 0.001 , Wilcoxon rank sum test), for mock- and CtrlL2-infected
196 samples, respectively. Finally, vinculin-Venus rates were 0.049 ± 0.037 intensity/min (n=654; mock-
197 infected) and 0.031 ± 0.030 intensity/min (n=842; CtrlL2-infected) p-value ≤ 0.001 , Wilcoxon rank
198 sum test) (Figure 3C). Because of the nature of FAs assembly, disassembly and protein recycling,
199 the reduced turnover might account for the reduced recruitment rates observed.

200

201 *Focal adhesions of infected cells exhibit resistance to disassembly induced by inhibitors of myosin II*

202 We further explored the stability phenotype exhibited by the FAs in CtrlL2-infected cells. Specifically,
203 we tested if they remained susceptible to the destabilizing effects of blebbistatin, a specific myosin II
204 inhibitor (Straight *et al.*, 2003). Myosin II function is to increase the mechanostress on FAs via its
205 action on the stress fibers, thus promoting their stability (Liu *et al.*, 2010). At 7 hpi, cells were
206 treated with $10 \mu\text{M}$ blebbistatin for 1 h. Fixed cells were stained with an antibody against paxillin. As
207 expected, after treatment with blebbistatin, control cells lost paxillin-containing FAs and F-actin-rich
208 stress fibers (SFs), as expected, whereas CtrlL2-infected cells treated with blebbistatin lost the SFs,
209 but retained the FAs (Figures 3D).

210 We showed above that increased FA numbers did not require *de novo* chlamydial protein
211 synthesis. Here, blebbistatin resistance of focal adhesions of CtrlL2-infected cells was monitored in
212 the presence or absence of chloramphenicol at 8 hpi (Figure 3E and S6), and remarkably, the FAs

213 of infected cells remained resistant to blebbistatin (Figure 3E). These results suggested that
214 possibly the same EB factor that modulated FAs numbers could also be modulating FA resistance
215 to blebbistatin. In addition, FAs displayed the same blebbistatin-resistant phenotype at 20 hpi
216 regardless of chloramphenicol treatment (Figure S3A and S3B).

217

218 *TarP mimics Chlamydia's modulation of focal adhesions numbers*

219 To gain mechanistic insight into FA modulation by *Chlamydia* infection, we investigated the role of
220 the T3SS effector TarP, which was an excellent candidate for the chloramphenicol-insensitive focal
221 adhesion stabilizing factor. TarP interacts with FAK via the leucine-aspartic acid (LD) motif
222 (residues LExLLPxLRAHL) and with vinculin via the two vinculin-binding sites (residues
223 LxxAAxNVTxxLS), which comprise TarP's vinculin binding domain (VBD) in the *C. trachomatis*
224 serovar L2 orthologue (Thwaites *et al.*, 2014, 2015). Additionally, when transiently transfected in
225 eukaryotic cells TarP localizes at the FAs (Figure S3C). Together, these properties of TarP make a
226 strong case for a role in FA modulation. We sought to determine the extent of TarP contribution to
227 the FAs phenotype observed in CtrlL2-infected cells, e.g. increased numbers, assembly and
228 disassembly rates and resistance to blebbistatin. Various constructs of CtrlL2 TarP ortholog fused
229 with mTurquoise2 fluorescence protein (Figure 4A) were transiently transfected in Cos7 cells for 20
230 h. The cells were fixed and stained with phalloidin and paxillin to visualize SFs and FAs,
231 respectively. In this experiment, we monitored simultaneously in transfected cells the localization of
232 TarP constructs at FAs, and the potential changes in FA numbers.

233 First, we evaluated the ability of the different TarP constructs to specifically localize to the
234 site of FAs (Figure 4B). We observed that ectopically expressed TarP^{1-1006Δ625-650} (in green)
235 localized to the paxillin-marked FAs (in red). It is important to note that TarP^{1-1006 Δ625-650}, which lacks
236 the proline-rich domain, was indistinguishable from intact TarP with regards to the recruitment of
237 FAK and vinculin at the plasma membrane (Thwaites *et al.*, 2014, 2015) or its localization to the
238 FAs (Figure S3C). TarP^{1-1006Δ625-650} was less prone to aggregate in the cytosol when ectopically
239 expressed. TarP⁸²⁹⁻⁹²⁹, which is comprised of the FAK binding domain (LD) localized to both FAs
240 and SFs, while TarP^{1-1006Δ625-650}, TarP⁸²⁹⁻¹⁰⁰⁶, and TarP⁹⁰⁵⁻¹⁰⁰⁶ localized to FAs only. The common

241 domain retained by these FA-localizing TarP derivatives was the vinculin-binding domain (VBD),
242 indicating that this domain is essential for specific localization to the host cell FAs. The TarP^{1-829Δ625-}
243 ⁶⁵⁰ derivative, which contained only the annotated actin-binding domain did not localize to FAs
244 possibly, reinforcing the role of the VBD in the FA localization of TarP.

245 Using confocal microscopy images, we were able to quantify the total FA number in cells
246 ectopically expressing the various TarP constructs described above. In this series of experiments,
247 we wanted to determine if TarP alone could modulate FA numbers. FAs were enumerated using
248 FIJI as previously described (see Materials and Methods for details), and data presented as a box-
249 and-whiskers plot (Figure 4C). The N1-mturquoise2 empty vector [43 ± 19 (n=26)] was the control
250 and provided the basal value. The quantification revealed that the FA numbers in cells transfected
251 with TarP derivatives harboring the LD or the VBD motifs were statistically significantly increased,
252 with mean values of 106 ± 45 (n=32), p-value ≤ 0.001 (TarP^{1-1006Δ625-650}); 70 ± 28 (n=43), p-value ≤
253 0.001 (TarP⁸²⁹⁻¹⁰⁰⁶), 58 ± 16 (n=20), p-value ≤ 0.001 (TarP⁸²⁹⁻⁹²⁹), and 68 ± 22 (n=19), p-value ≤
254 0.001 (TarP⁹⁰⁵⁻¹⁰⁰⁶). Additionally, the non-FA-localizing TarP^{1-829Δ625-650} construct did not differ from
255 the control empty vector [47 ± 20 (n=29) vs. 43 ± 19 (n=26), p-value > 0.05]. Wilcoxon rank sum
256 test was used to determine statistical significance.

257 Interestingly, we observed that TarP^{1-1006Δ625-650} produced more FAs than other TarP-
258 derived constructs, which suggested that other domains at the N-terminal portion of the protein is
259 necessary for a greater modulation of FAs. In addition, the VBD motif is important for both
260 increased numbers of and localization to focal adhesions.

261

262 *TarP modulates focal adhesion stability*

263 We then evaluated the resistance of FAs harboring the different deletion derivatives of TarP to
264 disassembly by a 1 h treatment with 10 μM blebbistatin. We found that TarP^{1-1006Δ625-650}, TarP⁸²⁹⁻¹⁰⁰⁶,
265 and TarP⁹⁰⁵⁻¹⁰⁰⁶ derivatives were able to confer resistance to blebbistatin-induced disassembly, as
266 shown by the retention of FAs (Figure 5A). All of these constructs retained the VBD region of TarP.
267 Interestingly, while the TarP⁸²⁹⁻⁹²⁹ protein, which is composed of the LD domain was able to localize
268 and increase FA numbers, it was ineffective in inducing blebbistatin-resistance, indicating that FA

269 localization is not sufficient. In other words, FA localization and blebbistatin resistance could be
270 uncoupled. Additionally, these results suggested that the interaction between TarP and vinculin is
271 required to confer FAs resistance to myosin II inhibition.

272 We also examined the effects of the TarP constructs in the recruitment and turnover rates
273 of paxillin-mCherry-marked FAs (Figure 5B and 5C, respectively) using TIRF microscopy (Movies
274 S5-S10). As described above for CtrlL2-infected cells, paxillin recruitment and turnover were both
275 decreased relative to mock-infected control (Figure 3B and 3C). In this experiment, we observed
276 that only TarP^{1-1006Δ625-650} mimicked the kinetics in infected cells. NIH3T3 cells transfected with
277 TarP^{1-1006Δ625-650} yielded the following recruitment and turnover rates: 0.054 ± 0.047 intensity/min
278 ($n=577$, $p\text{-value} \leq 0.001$) and 0.045 ± 0.040 intensity/min ($n=307$, $p\text{-value} \leq 0.001$), respectively.
279 TarP^{1-829Δ625-650} (retaining the LD, but not the VBD motif) was unable to increase FA numbers
280 (Figure 4C) and confer resistance to blebbistatin treatment (Figure 5A). Also, this TarP construct did
281 not significantly alter the recruitment [0.066 ± 0.050 intensity/min ($n=548$, $p\text{-value} \leq 0.001$; Wilcoxon
282 rank sum test)] and turnover rates [0.059 ± 0.048 intensity/min ($n=678$, $p\text{-value} > 0.05$; Wilcoxon
283 rank sum test)] of paxillin in FAs, when compared to the N1-mturquoise2 empty vector control
284 [recruitment: 0.063 ± 0.044 intensity/min ($n=777$) and turnover: 0.057 ± 0.038 intensity/min
285 ($n=814$)]. Surprisingly, no significant difference in recruitment and turnover rates between N1-
286 mturquoise2 and TarP⁸²⁹⁻⁹²⁹-transfected (LD only) cells [0.066 ± 0.050 intensity/min ($n=964$, $p\text{-value}$
287 > 0.05 ; Wilcoxon rank sum test)] and [0.059 ± 0.043 intensity/min ($n=1208$, $p\text{-value} > 0.05$;
288 Wilcoxon rank sum test)], respectively. Interestingly, TarP⁹²⁹⁻¹⁰⁰⁶ (VBD only) transfection had the
289 opposite effect of TarP^{1-1006Δ625-650} in the recruitment and turnover rates of paxillin in FAs. An
290 increase in FA recruitment and turnover rates was observed in cells transfected with TarP⁹²⁹⁻¹⁰⁰⁶
291 [0.077 ± 0.058 intensity/min ($n=618$, $p\text{-value} \leq 0.01$) and 0.067 ± 0.049 intensity/min ($n=671$, $p\text{-value}$
292 ≤ 0.001), respectively], in comparison with the N1-mturquoise2 control vector. Lastly, for cells
293 transfected with TarP⁸²⁹⁻¹⁰⁰⁶ an increase of recruitment rate was observed [0.073 ± 0.048
294 intensity/min ($n=1148$, $p\text{-value} \leq 0.001$; Wilcoxon rank sum test)]. However, no significant alteration
295 to the turnover rate between TarP⁸²⁹⁻¹⁰⁰⁶ [0.059 ± 0.042 intensity/min ($n=1616$, $p\text{-value} > 0.05$;
296 Wilcoxon rank sum test)] and N1-turquoise2 control vector was observed.

297

298 *Vinculin is required for Chlamydia-induced blebbistatin resistance*

299 In previous experiments, the VBD of TarP was proven to be essential to confer resistance to
300 disassembly via myosin II inhibition using its inhibitor, blebbistatin. To confirm this observation, this
301 resistance phenotype was evaluated in wild type ($vcf^{+/+}$) or vinculin double knock-out ($vcf^{-/-}$) mouse
302 embryo fibroblasts (Figure 6A). As expected when treated with 10 μ M of blebbistatin for 1 h mock-
303 infected MEFs $vcf^{+/+}$ and MEFs $vcf^{-/-}$ lost both paxillin-marked FAs and F-actin SFs. However, in
304 CtrlL2-infected cells although SFs were lost in both MEFs $vcf^{+/+}$ and $vcf^{-/-}$ MEFs, the FAs in $vcf^{+/+}$
305 were resistant to blebbistatin treatment. The same was not observed in $vcf^{-/-}$ MEFs, which lost FAs
306 despite CtrlL2 infection. This indicated that the eukaryotic protein vinculin is required by *Chlamydia*
307 to confer resistance to disassembly by myosin II inhibition.

308 To further implicate TarP-vinculin interaction in FA modulation, $vcf^{+/+}$ and $vcf^{-/-}$ MEFs were
309 transfected with the previously mentioned TarP constructs (Figure 4A). N1-mturquoise2 was used
310 as the control vector for possible side effects of transfection. It should be noted that the various
311 TarP constructs used here behaved similarly in Cos7 and wild type MEFs, with regards to
312 localization to focal adhesion and their ability to confer resistance to blebbistatin-mediated
313 disassembly (Figure S4 vs. Figures 4 and 5). As expected neither a specific localization nor FA
314 resistance to myosin II inhibition was observed in both $vcf^{+/+}$ or $vcf^{-/-}$ MEFs (Figure 6). In contrast,
315 TarP⁹⁰⁵⁻¹⁰⁰⁶ (VBD only) showed specific FA localization in $vcf^{+/+}$ MEFs, but this localization was lost
316 in $vcf^{-/-}$ cells. Additionally, resistance to blebbistatin of FAs was only observed in $vcf^{+/+}$ MEFs
317 transfected with TarP⁹⁰⁵⁻¹⁰⁰⁶, while FAs in $vcf^{-/-}$ cells transfected with the same construct remained
318 susceptible to blebbistatin treatment (Figure 6). Similarly, TarP^{1-1006 Δ 625-650} and TarP⁸²⁹⁻¹⁰⁰⁶ which
319 also specific localized to FAs and were able to confer FA resistance to myosin II inhibition displayed
320 a similar requirement for vinculin (Figure S4).

321

322 *Ectopic expression of TarP partially mimics the reorganization of paxillin and FAK in the focal*
323 *adhesions of Chlamydia-infected cells*

324 As shown above, TarP localized to focal adhesions in a manner that required the VBD motif.
325 Because FAs are highly organized structures, the insertion of a protein that binds to one or more
326 FA-associated proteins would likely cause changes to the spatial organization. To examine if the
327 localization of TarP within FAs resulted in changes to their organization, we performed super-
328 resolution imaging using interferometric photoactivation and localization microscopy (iPALM) of
329 CtrlL2-infected and mock-infected cells expressing paxillin-tdEos, vinculin-tdEos, or FAK-tdEos
330 (Figure 7). Presence of an inclusion in infected cells was confirmed by DIC (Figure S5). The
331 fluorescent protein tdEos is a photoactivated protein allowing the activation of individual fluorescent
332 molecules. This allows to precisely map the coordinates with three-dimensional nanoscale
333 resolution of the photoactivated fluorescent-tagged molecules (Betzig *et al.*, 2006). For cells
334 electroporated with tdEos-tagged constructs 50000 images were acquired per cell for analyses
335 iPALM imaging revealed the vertical distance of paxillin, FAK and vinculin in mock-infected cells to
336 be 50.5 nm (Figure 7A), 40.4 nm (Figure 7C), and 71 nm (Figure 7E), respectively, relative to the
337 gold fiducial marker embedded within the coverslip. These values are consistent with what has
338 been reported for these three FA proteins (Kanchanawong *et al.*, 2010). Unexpectedly, in CtrlL2-
339 infected cells, both paxillin-tdEos and FAK-tdEos were redistributed vertically in the FAs, with a
340 peak height of 176.9 nm (Figure 7B) and 96 nm (Figure 7D). Interestingly, vinculin showed no
341 alteration of vertical organization in the CtrlL2-infected cells with a peak at 71 nm (Figure 7F),
342 indicating that the reorganization specifically targeted a subset of the FA-associated proteins. The
343 markedly different paxillin and FAK distribution has never been reported for any experimental
344 system.

345 Next, we investigated the contribution of TarP to this reorganization phenotype. Paxillin-
346 tdEos expression plasmid was co-electroporated with individual deletion constructs of TarP-FLAG,
347 and iPALM images were obtained and processed to determine changes to the vertical organization.
348 For cells electroporated with Flag-tagged constructs 25000 images were acquired per cell for
349 analyses. We focused on the following TarP constructs: TarP^{1-1006Δ625-650}, TarP⁸²⁹⁻¹⁰⁰⁶ and TarP¹⁻

350 ^{829Δ625-650}. The first two constructs were able to localize to FAs and increase the numbers of FAs
351 and their level of resistance to blebbistatin. The normalized molecule count distribution data from
352 Ctrl2-infected and mock-infected samples were used as reference. As shown in Figure 8A, the
353 peak of pFH-TarP^{1-1006Δ625-650} (228.2 nm) was approximate with that of paxillin-tdEos (240.2) within
354 the same FA (Figure 8B). This mimicked the phenotype observed in Ctrl2-infected cells. We also
355 evaluated pFH-TarP⁸²⁹⁻¹⁰⁰⁶ (Figure 8C), which yielded intermediate phenotypes with regards to FA
356 number (Figure 4B). The protein distribution showed two peaks; one coincided well with the peak
357 for pFH-TarP^{1-1006Δ625-650}, and a second in an intermediate position. Monitoring the paxillin-tdEos
358 distribution in the same cells (Figure 8D), we observed segregation to the intermediate pFH-
359 TaRP⁸²⁹⁻¹⁰⁰⁶ peak and mock-infected peak. A TarP construct lacking LD and the VBD (TarP<sup>1-829Δ625-
360 650</sup>), and thus unable to localize to FAs failed to redistribute paxillin-tdEos (Figure 8E). These data
361 show that LD and VBD domains of TarP could induce an intermediate reorganization phenotype
362 with regards to paxillin. In addition, the intermediate phenotype acquired from the pFH-TaRP⁸²⁹⁻¹⁰⁰⁶
363 samples was consistent with its intermediate effects on FA numbers and the hypotheses of other N-
364 terminus domains of TarP being involved in FA modulation. However, as previously noted, these
365 domains, which were presumably retained in the TarP^{1-829Δ625-650}, construct would not be able to
366 perform their function in the absence of the FA targeting domains.

367 **Discussion**

368 With a large portion of its intracellular developmental cycle spent in the non-infectious RB form, it is
369 imperative for *Chlamydia trachomatis* and other chlamydial species to develop a strategy to
370 counteract the constant epithelial cell shedding observed *in vivo* (Rosenblatt, Raff and Cramer,
371 2001; Mysorekar *et al.*, 2002; AbdelRahman and Belland, 2005). Epithelial extrusion is an anti-
372 microbial response that *Chlamydia* must deal with to ensure the completion of its developmental
373 cycle and the formation of infectious particles that enable subsequent rounds of infection. In this
374 report, we described the direct modulation of FAs stability that required the T3SS effector TarP and
375 its interaction with the FA-associated protein vinculin.

376 Focal adhesion changes were observed throughout infection, as early as 2 hpi, which led to
377 the hypothesis that an EB-associated protein could be involved. TarP was identified as an ideal
378 candidate based on its association with EBs and the presence of binding sites, i.e. LD and VBD for
379 FAK and vinculin, respectively. In this report, it was observed that FA modulation could be observed
380 up to 20 hpi even when chlamydial protein synthesis was inhibited starting at 0 hpi. We propose that
381 TarP is present throughout infection, albeit at developmentally regulated levels to sustain the
382 modulated character of FAs in infected cells. For TarP to sustain its modulation of FAs in infected
383 cells, the protein would have to be either stable from the time it is translocated during invasion
384 and/or synthesized throughout infection. Indeed, using β -lactamase fusions, Mueller and Fields
385 (2015) were able to show constant expression and translocation of TarP from its native promoter
386 throughout infection. We also report that the pool of translocated TarP was relatively stable (Figure
387 S3E). In this experiment, infection of cultured cells was performed in the constant presence of
388 chloramphenicol to prevent *de novo* TarP synthesis. We observed by Western blot that TarP was
389 present up to 24 hpi, the latest time monitored. Thus, it appears that in chloramphenicol-treated
390 infected cells, the enduring presence of TarP correlated with the increase number of FAs
391 phenotype. Furthermore, while relative TarP protein levels during infection decreased mid-stage, it
392 was never absent (Clifton *et al.*, 2004). Importantly, TarP continued to be translocated throughout
393 infection as indicated by reactivity to the anti-phosphotyrosine 4G10 (Mueller and Fields, 2015).

394 Currently, it is impossible to generate *Chlamydiae* TarP mutants owing to its indispensable
395 role in the invasion process of this obligate intracellular pathogen. It was also technically difficult to
396 locate endogenous translocated TarP molecules likely due to their limiting amount compounded
397 with the significant dilution once in the host cell cytosol, and distribution among the host cell's FAs.
398 Nevertheless, using similar approaches (e.g. ectopic expression) for studies of the subcellular
399 localization of endogenous T3SS effectors, we were able to demonstrate the FA localization of TarP
400 and its crucial role in FA modulation by *Chlamydia*. The FA localization was specific, being
401 dependent on the respective FAK and vinculin binding domains in TarP. A side-by-side comparison
402 of the respective effects of infection and TarP transfection on FAs enabled us to determine the
403 extent of the contribution of TarP to the FA phenotypes. *Chlamydia* infection led to increased
404 numbers and stability of FAs. The latter involved resistance to disassembly induced by treatment
405 with blebbistatin, which is an inhibitor of myosin II (Feng *et al.*, 1999; Wang *et al.*, 2008; Liu *et al.*,
406 2010). Importantly, TarP makes a significant contribution to the various FA phenotypes observed in
407 infected cells. Based on our TarP transfection studies, TarP^{1-1006Δ625-650}, TarP⁸²⁹⁻¹⁰⁰⁶, TarP⁸²⁹⁻⁹²⁹, and
408 TarP⁹⁰⁵⁻¹⁰⁰⁶ were involved in FA localization. Increased FA numbers were observed in cells
409 ectopically expressing the same four TarP constructs. FAs in cells expressing TarP^{1-1006Δ625-650},
410 TarP⁸²⁹⁻¹⁰⁰⁶, and TarP⁹⁰⁵⁻¹⁰⁰⁶ remained intact during blebbistatin treatment, revealing the role of the
411 VBD motif of TarP. Additionally, only TarP^{1-1006Δ625-650} was able to mimic Ctrl2 infection in relation to
412 the recruitment and turnover of FAs. From these experiments, it was determined that TarP's FA
413 targeting domain VBD was sufficient to modulate FA, however other domain(s) in the N-terminus
414 were necessary to fully mimic Ctrl2 infection. Resistance of FA to myosin II inhibition required the
415 VBD domain. In short, the VBD motif plays an important role in the modulation of FAs by TarP. We
416 further implicated the TarP-vinculin interaction via the VBD domain in various aspects of FA
417 modulation, specifically FA localization and FA resistance to disassembly by blebbistatin.

418 How might TarP affect FA stability? TarP does not have any known enzymatic activities,
419 such as phosphorylation. Instead its known roles are as a protein scaffold to which signaling
420 molecules are recruited, and a bacterial actin nucleator (Clifton *et al.*, 2004; Jewett *et al.*, 2006;
421 Lane *et al.*, 2008). The reorganization of FAs observed in TarP-transfected cells is likely to be a

422 significant determinant of FAs stability. How reorganization translates to stability (i.e. resistance to
423 blebbistatin) is not clear, but that the same domain of TarP being implicated in different FA
424 changes, including the vertical reorganization, indicates an important role for this effector. To our
425 knowledge, changes to the vertical organization of FAs have not been described in any
426 experimental system, and thus, the mechanism for how the reorganization translates to stability is
427 not known. A possibility is the displacement of signaling molecules, disrupting protein-protein
428 interactions essential to normal FA dynamics. The data presented here that demonstrated the
429 essential role of the VBD domain in modifying the vertical organization of FAs is consistent with this
430 idea. It is also possible that the binding of TarP to vinculin may result in the disruption of the
431 interaction between the tail and head domains of vinculin, preventing the inactivation of vinculin in
432 the absence of myosin II mechanical tension. Indeed, in MEFs *vcl*^{-/-} expressing truncated versions
433 of vinculin lacking the tail domain were resistant to the loss of mechanical tension (Carisey *et al.*,
434 2013). The removal of the tail domain constitutively activated vinculin by preventing its inactivation
435 through self-folding. Additionally, Carisey *et al.*, (2013) also demonstrated that vinculin regulates the
436 release of other FA proteins, such as, talin, paxillin, FAK, ILK, among others. A similar stabilizing
437 mechanism could be involved in CtrL2-dependent FA resistance to the loss of mechanical tension
438 exerted by myosin II. The interaction between TarP and vinculin might prevent its inactivation and
439 consequently stabilizes the FA complexes to the extent that mimics the constitutively activated
440 vinculin.

441 In this report, we identified a potential virulence strategy of *Chlamydia* that counteracts
442 exfoliation of epithelial cells from the mucosal surface. We quantified the kinetics of focal adhesion
443 formation and turnover, described a novel vertical reorganization phenotype of FAs in infected cells,
444 and identified a type III effector (TarP) and its interacting partner (vinculin) that mediate these
445 changes. TarP was initially identified as an invasion-associated protein, and in this report, we
446 assign to it a post-invasion role, raising new questions, including the extent of the role TarP plays in
447 survival and pathogenesis.

448

449 **Materials and Methods**

450 **Cell culture.** Cos7 (ATCC CRL-1651), NIH3T3 (kindly supplied by Hector Aguilar-Carreño ATCC
451 CRL-1658) and HeLa 229 (ATCC CCL-2.1) MEFs *vcl*^{-/-} and matched HeLa 229 MEFs *vcl*^{+/+} (Marg *et*
452 *al.*, 2010) (were kindly provided by Dr. Wolfgang Ziegler Hannover Medical School).cells were culture
453 using Dulbecco's Modified Eagle Medium (DMEM) (Thermofisher scientific, 11960-085). Media
454 were supplemented with 10% fetal bovine serum (Sigma, F0804-500ML), 2mM L-glutamine, and
455 10µg/ml gentamicin. The human keratinocytes HaCaT cells (kindly supplied by Dr. Kristin M. Braun)
456 were cultured in 3 parts DMEM and 1 part Ham's F-12 Nutrient Mix (Thermofisher scientific
457 11765054), supplemented with 10% fetal bovine serum (Sigma, F0804-500ML), 2 mM L-glutamine,
458 10µg/ml gentamicin, insulin (Sigma I9278-5ML) and hydrocortisone cholera toxin EGF (HCE)
459 cocktail. *Chlamydia trachomatis* serovar L2 (L2/434/Bu) was propagated in HeLa 229. EBs were
460 harvested by discontinuous density gradient centrifugation in gastrografin (Bracco Diagnostics), as
461 previously described (Thwaites *et al.*, 2014).

462

463 ***Chlamydia* infections.** Cells were infected with *Chlamydia trachomatis* serovar L2 (L2/434/Bu,
464 CtrL2) at the multiplicity of infection MOI of 5, for 20 h, and of 25, for 8 h, in ice cold serum-free
465 DMEM. Cells were centrifuged at 1000 rpm for 5 min at 4 °C to synchronize the infection. After
466 centrifugation, the inoculum was replaced with warm DMEM supplemented with 10% fetal bovine
467 serum, 2 mM L-glutamine, and 10µg/ml gentamicin. In parallel, a mock-infected control was made
468 following the same protocol but without *Chlamydia* infectious particles.

469

470 **Immunostaining.** Cells were grown on Fibronectin coated coverslips (Neuvitro, GG-12-fibronectin)
471 for the duration of the experiment. At the pre-determined, time cells were rinsed with Hank's
472 Balanced Salt Solution (HBSS) (Thermofisher scientific, 14025-100) and fixed using 4%
473 paraformaldehyde (PFA) in PBS pH 7.4 (Gibco, 14190-094) for 20 min at room temperature. The
474 fixed cells were then permeabilized using PBS with 0.2% Triton X-100. Subsequently,
475 permeabilized cells were incubated with 1% BSA (Sigma, A9418) in PBS, for 30 min at room
476 temperature, to block non-specific antigen binding. Cells were then incubated with the primary

477 antibodies overnight at 4°C with rocking. The primary antibodies used in this study were rabbit
478 polyclonal antibody against FAK phosphorylated at tyrosine 397 (pFAK-Y397) (Abcam, ab4803),
479 rabbit monoclonal antibody paxillin (Abcam, ab32084), mouse monoclonal antibody vinculin
480 (Abcam, ab18058), Mouse monoclonal Flag-tag antibody (Cell Signalling, 8146S) mouse
481 monoclonal antibody *Chlamydia* LPS (Abcam, ab62708) and convalescent human sera. Afterwards
482 cells were incubated with appropriate fluorescently conjugated secondary antibodies and, when
483 specified, with DAPI (Roche, 10236276001) and Alexa flour 488 phalloidin stains, for 1 hr at room
484 temperature, with rocking. In this study, the following secondary antibodies were used: goat anti-
485 rabbit Alexa flour 488 (Thermofisher Scientific, A11008), goat anti-rabbit Alexa flour 633
486 (Thermofisher Scientific, A21071), goat anti-mouse Alexa flour 594 (Thermofisher Scientific,
487 A11005), goat anti-human Alexa flour 647 (Thermofisher scientific A-21445). Following staining, the
488 coverslips were mounted with Mowiol, and visualized in ZEISS LSM 710 confocal microscope, in
489 the Microscopy and Histology Core Facility at the University of Aberdeen, or the Leica SP8 confocal
490 microscope in Washington State University Integrative Physiology and Neuroscience advance
491 image equipment. FIJI software (Schindelin *et al.*, 2012; Schneider, Rasband and Eliceiri, 2012)
492 was used to generate the final images.

493

494 **Time-lapse microscopy.** For live-cell imaging of FAs NIH3T3 cells were seeded on ibidi μ -slide 8
495 well chambers with fibronectin coating (ibidi, 80823) at the recommended seeding density and left
496 overnight in a 37 °C, 5% CO₂ incubator. The following day, cells were infected with CtrlL2 with a
497 MOI of 5. At 2 h post-infection, the cells were transfected with either Vinculin-venus (Grashoff *et al.*,
498 2010) a gift from Martin Schwartz, (Addgene, 27300), paxillin-pEGFP (Laukaitis *et al.*, 2001) a gift
499 from Rick Horwitz, (Addgene, 15233), or FAK-GFP (Gu *et al.*, 1999; Lane *et al.*, 2008) a gift from
500 Kenneth Yamada, (Addgene, 50515) using Lipofectamine 3000 transfection reagent (Thermofisher
501 Scientific, L3000008), following the manufacture instructions. After 20 to 22 h, time lapsed images
502 of transfected cells were obtained using a Leica SD6000 AF in TIRF mode, in Washington State
503 University IPN advance image equipment. Images of the GFP-tagged proteins were collected every

504 minute for 90 min. The time lapse images were uploaded to the Focal adhesion Analysis server
505 (Berginski and Gomez, 2013).

506

507 **De novo protein inhibition.** Cos7 cells were cultured as previously described. Prior to infection,
508 cells and EB particles were treated with 60 µg/ml of chloramphenicol (Sigma C0378) for 30 min.
509 Cells and EBs were kept in chloramphenicol supplemented DMEM until fixation. Cells were fixed at
510 8 or 20 h post-infection and were immunostained as described above.

511

512 **Cloning and transfection of TarP constructs.** A summary of the primers used in this study is
513 provided in Table S1. Initially TarP¹⁻¹⁰⁰⁶, TarP⁸²⁹⁻¹⁰⁰⁶, TarP⁸²⁹⁻⁹²⁹ and TarP⁹⁰⁵⁻¹⁰⁰⁶ were PCR amplified
514 from Ctrl2 genomic DNA using the primers combination 1-2, 5-2, 5-6 and 4-2, respectively. A
515 *Bam*H1 (reverse primer) and *Kpn*I (forward primer) restriction sites were used for fusion with the
516 N1-mturquoise2 plasmid. The TarP^{1-1006Δ650-625} was obtained using the 7-8 primer pair for PCR
517 amplification from TarP¹⁻¹⁰⁰⁶-mturquoise2 fusion plasmid. The primers were created to amplify the
518 whole TarP¹⁻¹⁰⁰⁶-mturquoise2 except the nucleotides that constitute the proline rich domain (PRD)
519 625-650. The resulting PCR product was recombined using in-Fusion HD cloning plus CE
520 (Clontech, 638916) to create a functional circular plasmid. TarP^{1-829Δ625-650} was PCR amplified from
521 the TarP^{1-1006Δ625-650}-mturquoise2 plasmid using the primers pair 1-3. The same restriction enzymes
522 were used to clone these fragments into N1-mturquoise2. Transformations using restriction
523 enzymes recombination were made into chemically competent Top10 (invitrogen) *E. coli*, and
524 vectors sequence was verified using sequencing (Eurofins) The construct pFH-TarP^{1-1006Δ625-650} and
525 pFH-TarP^{1-829Δ625-650} used for super-resolution experiments was PCR amplified from TarP<sup>1-1006Δ625-
526 650</sup>-mturquoise2 using primers combination 9-10 and 9-17, respectively. To use homology cloning
527 the vector backbone 1436 pcDNA3-Flag-HA, kindly provided by William Sellers (Addgene 10792),
528 was linearized by PCR using the primers pair 11-12 and 11-18, creating homology overhang
529 regions to the TarP^{1-1006 Δ625-650} and TarP^{1-829 Δ625-650}, respectively. TarP⁸²⁹⁻¹⁰⁰⁶ was amplified from
530 Ctrl2 genomic DNA using the primer pairs 13-14. To use homology cloning the vector backbone
531 1436 pcDNA3-Flag-HA was linearized by PCR using the primer pair 15-16. Fragments and vector

532 backbone were recombined using in-Fusion HD cloning plus CE (Clontech, 638916) to create a
533 functional circular plasmid. Transformations using homology recombination were made into
534 chemically competent Stellar (Clontech) *E. coli*, and vectors sequence was verified using
535 sequencing (Eurofins). The pcDNA3-Flag-Apex-Nes was a gift from Alice Ting (Addgene, 49386).
536 The N1-mturquoise2 (Addgene, 54843). Transfections were done as described above. For iPALM
537 experiments 1µg of DNA and 2µl of sheared salmon sperm DNA were mixed together in 15µl of
538 Opti-MEM (Thermofisher scientific, 31985062), and kept on ice for 15 min. 1×10^6 Cos7 cells were
539 resuspended in 200µl of cold Opti-MEM, mixed with the DNA solution and kept on ice for 30
540 seconds. Cells and DNA suspension were transferred to a 4mm gap cuvette (BioRad, 1652088)
541 and electroporated using BioRad Gene Pulser XCell using the following settings: 190V; 950uF;
542 infinity. After electroporation 1.5ml of warm growth media was added. 400µl of cell solution was
543 added to a 6 well plate well containing 1.5ml of warm growth media and the gold fiducial coverslip.
544 Cells were incubated 37°C, 4% CO₂ for 4 h to adhere to the gold fiducial coverslip. Cells were
545 washed to remove dead cells debris and further incubated for 20 h.

546

547 **Trypsin assay.** Cells were plated in 24 well plates and incubated at 37°C and 5% CO₂, until 80-
548 90% confluency. Afterwards, cells were infected with CtrlL2 with a multiplicity of infection of 5 for 20
549 h. Cells were then treated with 0.01% trypsin diluted in serum-free DMEM media at 37°C, for 0, 10,
550 20, 30, or 35 min. Cells were fixed with 4% PFA, carefully washed with PBS and stained with DAPI
551 to count the number of remaining cells as well as to visualize *Chlamydia* inclusions. Images were
552 taken using Nikon eclipse TE2000-U.

553

554 **iPALM imaging and analysis.** The principle of instrumentation for iPALM imaging and analysis
555 were performed as previously described (Shtengel *et al.*, 2009; Kanchanawong *et al.*, 2010) with
556 the following modifications. After 24°C of transfection cells plated in gold fiducial coverslip were
557 fixed with 0.8% PFA and 0.1% glutaraldehyde (Sigma G7526-10ML) solution (in PBS) for 10 min.
558 After fixation cells were washed 3 times with PBS and quenched using 1% NaBH₄ (Sigma, 452882-
559 25G) solution (in PBS) for 7 min. Cells were then washed again 3 times with PBS. After washing

560 cells were immunostained (when necessary) and/or processed for iPALM imaging as previously
561 described (Kanchanawong *et al.*, 2010). The vertical coordinates relative to the golden fiducial
562 markers are indicating by a color scale from red (0 nm) to purple (250 nm).

563

564

565 **Acknowledgments**

566 We would like to thank Dr. Raphael Valdivia (Duke University) for the generous gift of the TarP
567 antibody; Drs. Martin Schwartz, Rick Horwitz, Kenneth Yamada, William Sellers, Alice Ting, and
568 Michael Davidson for various constructs through Addgene; the services provided by the Aberdeen
569 Imaging Facility in the Institute for Medical Sciences and the WSU Integrated Physiology and
570 Neuroscience imaging facilities; and Satya Khuon (AIC Janelia) for technical help and advice. This
571 project was supported by grants from the University of Aberdeen's Knowledge Exchange Transfer
572 Fund, the National Institute for Food and Agriculture (#1010265), National Institutes of Health
573 (AI065545), and start-up funds from the WSU College of Veterinary Medicine to R.A.C. A.T.P. and
574 A.T.N. are recipients of the Fundação para a Ciência e Tecnologia, SFRH/BD/76741/2011 and
575 SFRH/BD/86670/2012, respectively. T.R.T. is a Medical Research Council studentship awardee.
576 iPALM data used in this publication was produced in collaboration with the Advanced Imaging
577 Center, a facility jointly supported by the Gordon and Betty Moore Foundation and Howard Hughes
578 Medical Institute at the Janelia Research Campus.

579

580 **Author Contributions**

581 Conceptualization, A.T.P., A.T.N. and R.A.C.; Methodology, A.T.P., J.A., and R.A.C.; Software,
582 J.A.; Formal Analysis, A.T.P.; Investigation, A.T.P., A.T.N, J.A., and T.R.T.; Writing – Original Draft,
583 A.T.P., and R.A.C.; Writing – Review & Editing, A.T.P., A.T.N. and R.A.C; Funding Acquisition,
584 A.T.P., A.T.N. and R.A.C.; Resources, J.A., T.L.C. and R.A.C.; Supervision, T.L.C. and R.A.C.

585 **Conflict of Interest**

586 The authors have declared that no competing or financial interests exist.

587 **References**

- 588 AbdelRahman, Y. M. and Belland, R. J. (2005) 'The chlamydial developmental cycle', *FEMS*
589 *Microbiology Reviews*, 29(5), pp. 949–959. doi: 10.1016/j.femsre.2005.03.002.
- 590 Berginski, M. E. and Gomez, S. M. (2013) 'The Focal Adhesion Analysis Server: a web tool for
591 analyzing focal adhesion dynamics.', *F1000Research*, 2, p. 68. doi: 10.12688/f1000research.2-
592 68.v1.
- 593 Betzig, E. *et al.* (2006) 'Imaging Intracellular Fluorescent Proteins at Nanometer Resolution',
594 *Science*, 313(5793), pp. 1642–1645. doi: 10.1126/science.1127344.
- 595 Borradori, L. and Sonnenberg, A. (1999) 'Structure and function of hemidesmosomes: More than
596 simple adhesion complexes', *Journal of Investigative Dermatology*. Elsevier Masson SAS, 112(4),
597 pp. 411–418. doi: 10.1046/j.1523-1747.1999.00546.x.
- 598 Carisey, A. *et al.* (2013) 'Vinculin regulates the recruitment and release of core focal adhesion
599 proteins in a force-dependent manner.', *Current biology*: CB, 23(4), pp. 271–81. doi:
600 10.1016/j.cub.2013.01.009.
- 601 Clifton, D. R. *et al.* (2004) 'A chlamydial type III translocated protein is tyrosine-phosphorylated at
602 the site of entry and associated with recruitment of actin.', *Proceedings of the National Academy of*
603 *Sciences of the United States of America*, 101(27), pp. 10166–71. doi: 10.1073/pnas.0402829101.
- 604 Feng, J. *et al.* (1999) 'Inhibitory Phosphorylation Site for Rho-associated Kinase on Smooth Muscle
605 Myosin Phosphatase', *Journal of Biological Chemistry*, 274(52), pp. 37385–37390. doi:
606 10.1074/jbc.274.52.37385.
- 607 Geiger, B. *et al.* (2001) 'Transmembrane crosstalk between the extracellular matrix--cytoskeleton
608 crosstalk.', *Nature reviews. Molecular cell biology*, 2(11), pp. 793–805. doi: 10.1038/35099066.
- 609 Grashoff, C. *et al.* (2010) 'Measuring mechanical tension across vinculin reveals regulation of focal
610 adhesion dynamics.', *Nature*, 466(7303), pp. 263–6. doi: 10.1038/nature09198.
- 611 Gu, J. *et al.* (1999) 'Shc and FAK differentially regulate cell motility and directionality modulated by
612 PTEN.', *The Journal of cell biology*, 146(2), pp. 389–403. Available at:
613 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2156182&tool=pmcentrez&rendertype=a](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2156182&tool=pmcentrez&rendertype=abstract)
614 [bstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2156182&tool=pmcentrez&rendertype=abstract) (Accessed: 23 February 2016).

- 615 Heymann, J. *et al.* (2013) 'Chlamydia trachomatis infection prevents front-rear polarity of migrating
616 HeLa cells', *Cellular Microbiology*, 15(7), pp. 1059–1069. doi: 10.1111/cmi.12114.
- 617 Jewett, T. J. *et al.* (2006) 'Chlamydial TARP is a bacterial nucleator of actin.', *Proceedings of the*
618 *National Academy of Sciences of the United States of America*, 103(42)(42), pp. 15599–15604. doi:
619 10.1073/pnas.0603044103.
- 620 Kanchanawong, P. *et al.* (2010) 'Nanoscale architecture of integrin-based cell adhesions.', *Nature*.
621 Nature Publishing Group, 468(7323), pp. 580–584. doi: 10.1038/nature09621.
- 622 Kim, D.-H. and Wirtz, D. (2013) 'Focal adhesion size uniquely predicts cell migration', *The FASEB*
623 *Journal*, 27(4), pp. 1351–1361. doi: 10.1096/fj.12-220160.
- 624 Kim, M. *et al.* (2009) 'Bacteria hijack integrin-linked kinase to stabilize focal adhesions and block
625 cell detachment.', *Nature*, 459(7246), pp. 578–582. doi: 10.1038/nature07952.
- 626 Kim, M. *et al.* (2010) 'Reinforcement of epithelial cell adhesion to basement membrane by a
627 bacterial pathogen as a new infectious stratagem', *Virulence*, 1(April 2010), pp. 52–55. doi:
628 10.1038/nature07952.he.
- 629 Kumar, Y. and Valdivia, R. H. (2008) 'Reorganization of the host cytoskeleton by the intracellular
630 pathogen Chlamydia trachomatis', *Commun Integr Biol*, 1(2), pp. 175–177. doi:
631 10.1016/j.chom.2008.05.018.www.landesbioscience.com.
- 632 Lane, B. J. *et al.* (2008) 'Chlamydial entry involves TARP binding of guanine nucleotide exchange
633 factors', *PLoS Pathogens*, 4(3). doi: 10.1371/journal.ppat.1000014.
- 634 Laukaitis, C. M. *et al.* (2001) 'Differential dynamics of alpha 5 integrin, paxillin, and alpha-actinin
635 during formation and disassembly of adhesions in migrating cells.', *The Journal of cell biology*,
636 153(7), pp. 1427–40. Available at:
637 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2150721&tool=pmcentrez&rendertype=a](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2150721&tool=pmcentrez&rendertype=abstract)
638 [bstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2150721&tool=pmcentrez&rendertype=abstract) (Accessed: 23 February 2016).
- 639 Liu, Z. *et al.* (2010) 'Blebbistatin inhibits contraction and accelerates migration in mouse hepatic
640 stellate cells.', *British journal of pharmacology*, 159(2), pp. 304–15. doi: 10.1111/j.1476-
641 5381.2009.00477.x.
- 642 Marg, S. *et al.* (2010) 'The Vinculin-ΔIn20/21 Mouse Characteristics of a Constitutive, Actin-Binding

- 643 Deficient Splice Variant of Vinculin', *PloS one*, 5(7), p. e11530. doi: 10.1371/journal.pone.0011530.
- 644 Morita-Ishihara, T. *et al.* (2013) 'EspO1-2 Regulates EspM2-Mediated RhoA Activity to Stabilize
645 Formation of Focal Adhesions in Enterohemorrhagic Escherichia coli-Infected Host Cells', *PLoS*
646 *ONE*, 8(2). doi: 10.1371/journal.pone.0055960.
- 647 Mueller, K. E. and Fields, K. A. (2015) 'Application of b-lactamase reporter fusions as an indicator of
648 effector protein secretion during infections with the obligate intracellular pathogen Chlamydia
649 trachomatis', *PLoS ONE*, 10(8), pp. 1–18. doi: 10.1371/journal.pone.0135295.
- 650 Mysorekar, I. U. *et al.* (2002) 'Molecular regulation of urothelial renewal and host defenses during
651 infection with uropathogenic Escherichia coli.', *The Journal of biological chemistry*, 277(9), pp.
652 7412–9. doi: 10.1074/jbc.M110560200.
- 653 Nagano, M. *et al.* (2012) 'Turnover of focal adhesions and cancer cell migration', *International*
654 *Journal of Cell Biology*, 2012. doi: 10.1155/2012/310616.
- 655 Rosenblatt, J., Raff, M. C. and Cramer, L. P. (2001) 'An epithelial cell destined for apoptosis signals
656 its neighbors to extrude it by an actin- and myosin-dependent mechanism', *Current Biology*, 11(23),
657 pp. 1847–1857. doi: 10.1016/S0960-9822(01)00587-5.
- 658 Schindelin, J. *et al.* (2012) 'Fiji: an open-source platform for biological-image analysis.', *Nature*
659 *methods*, 9(7), pp. 676–82. doi: 10.1038/nmeth.2019.
- 660 Schneider, C. A., Rasband, W. S. and Eliceiri, K. W. (2012) 'NIH Image to ImageJ: 25 years of
661 image analysis.', *Nature methods*, 9(7), pp. 671–5. Available at:
662 <http://www.ncbi.nlm.nih.gov/pubmed/22930834> (Accessed: 17 July 2014).
- 663 Shames, S. R. R. *et al.* (2010) 'The pathogenic E. coli type III effector EspZ interacts with host
664 CD98 and facilitates host cell prosurvival signalling', *Cellular Microbiology*, 12(9), pp. 1322–1339.
665 doi: 10.1111/j.1462-5822.2010.01470.x.
- 666 Shtengel, G. *et al.* (2009) 'Interferometric fluorescent super-resolution microscopy resolves 3D
667 cellular ultrastructure.', *Proceedings of the National Academy of Sciences of the United States of*
668 *America*, 106(9), pp. 3125–3130. doi: 10.1073/pnas.0813131106.
- 669 Straight, A. F. *et al.* (2003) 'Dissecting temporal and spatial control of cytokinesis with a myosin II
670 Inhibitor.', *Science (New York, N.Y.)*, 299(5613), pp. 1743–7. doi: 10.1126/science.1081412.

671 Thwaites, T. *et al.* (2014) 'The Chlamydia effector TarP mimics the mammalian leucine-aspartic
672 acid motif of paxillin to subvert the focal adhesion kinase during invasion', *Journal of Biological*
673 *Chemistry*, 289(44), pp. 30426–30442. doi: 10.1074/jbc.M114.604876.

674 Thwaites, T. R. *et al.* (2015) 'Vinculin Interacts with the Chlamydia Effector TarP Via a Tripartite
675 Vinculin Binding Domain to Mediate Actin Recruitment and Assembly at the Plasma Membrane',
676 *Frontiers in Cellular and Infection Microbiology*, 5(November). doi: 10.3389/fcimb.2015.00088.

677 Vossenkämper, A., Macdonald, T. T. T. and Marchès, O. (2011) 'Always one step ahead: How
678 pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune
679 system.', *Journal of inflammation (London, England)*. BioMed Central Ltd, 8(1), p. 11. doi:
680 10.1186/1476-9255-8-11.

681 Wang, H. H. H. *et al.* (2008) 'Blebbistatin inhibits the chemotaxis of vascular smooth muscle cells by
682 disrupting the myosin II-actin interaction.', *American journal of physiology. Heart and circulatory*
683 *physiology*, 294(5), pp. H2060–H2068. doi: 10.1152/ajpheart.00970.2007.

684 Zaidel-Bar, R. *et al.* (2007) 'Functional atlas of the integrin adhesome.', *Nature cell biology*, 9(8), pp.
685 858–67. doi: 10.1038/ncb0807-858.

686

687 **Figure legends**

688

689 **Figure 1.** *Chlamydia* infection of confluent monolayers confers resistance to detachment by
690 trypsinization. HeLa cells were infected with CtrlL2 or mock-infected for 20 h prior to the start of the
691 experiment. Cells were treated with 0.01% trypsin for the different time points. (A) Cells were
692 visualised by immunostaining of the nuclei and the chlamydial inclusions using DAPI (white).
693 Infected cells are indicated by red arrows. Scale bar: 100 μ m. Representative figure of 2
694 independent experiments. (B) The number of nuclei per field of view was counted and data is
695 represented as box-and-whisker plots. Whiskers represent the lowest and highest data point still
696 within 1.5 times the interquartile range. The light blue asterisks indicate significant difference
697 relative to the 0 min time point of each condition (Wilcoxon rank sum test ** = $p < 0.01$, *** =
698 $p < 0.001$). The dark blue asterisks indicate significant differences between the mock-infected control
699 and *C. trachomatis* L2 infected at the same time point. The black cross shows the average for each
700 experimental samplel.

701

702 **Figure 2.** *C. trachomatis* increases host cell focal adhesion numbers independently of chlamydial
703 *de novo* protein synthesis. CtrlL2 infection increases the numbers of focal adhesions marked by
704 vinculin (A, C) and paxillin (B, D). Cos7 cells infected or mock-infected were monitored at 8 or 20
705 hpi with and without Chloramphenicol for changes to focal adhesions marked by vinculin (A) and
706 paxillin (B), all in green. *Chlamydia* is shown in red. Infected cells showed increased numbers of FA
707 markers when compared to mock-infected cells (top row) in both time points and in chloramphenicol
708 treatment. Scale bar length 10 μ m. The number of vinculin (C) and paxillin (D) stained focal
709 adhesions in infected and mock-infected cells were counted and data is represented as box-and-
710 whisker plots. Whiskers represent the lowest and highest data point still within 1.5 times the
711 interquartile range. The light blue asterisks indicate significant difference relative to the mock-
712 infected control (Wilcoxon rank sum test ** = $p < 0.01$, *** = $p < 0.001$). The black cross shows the
713 average for each experimental sample.

714

715 **Figure 3.** Quantitative analyses reveal significant changes to the dynamics of focal adhesion in
716 infected cells. (A-C) NIH3T3 cells CtrlL2-infected or mock-infected were transfected with different
717 GFP-tagged constructs of FAK, paxillin or vinculin, and monitored between 20 to 22 hpi for 90 min.
718 (A) Visualization of example cells for paxillin-pEGFP focal adhesion marker. See Figure S2E for
719 example of cells transfected with FAK-pEGFP and vinculin-venus focal adhesion markers. All focal
720 adhesions detected in each frame were given a color ranging from blue (first frame) to red (last
721 frame). Scale bar length 10 μ m. (B) and (C) are box-and-whiskers plots that quantify the effect of
722 *Chlamydia* infection on focal adhesion, specifically the recruitment (B) and turnover (C) of focal
723 adhesions labeled with FAK, paxillin, or vinculin. Whiskers represent the lowest and highest data
724 point still within 1.5 times the interquartile range. For statistical analyses the Wilcoxon Rank sum
725 test was used (***) = $p < 0.001$). See Figure S2F for DIC images showing the presence or absence of
726 CtrlL2 inclusions of example cells. (D, E) *Chlamydia* infected cells are resistant to blebbistatin. Cos7
727 cells were mock-infected (top panels) or infected with CtrlL2 for 8 (bottom panels) and 20 h (see
728 Figure S3A and S3B). Cells were fixed and stained for the focal adhesion marker paxillin (in green),
729 F-actin (in red) and human serum for *C. trachomatis* (white). Cells were also mock- (D) or pre-
730 treated (E) with chloramphenicol (Cm) followed by infection of live EBs. The Cm treatment was
731 maintained for the duration of the experiment. Cells without blebbistatin treatment showed clear F-
732 actin stress fibres and paxillin-labeled focal adhesions. (D) Cells were mock treated (first and third
733 row) or treated with 10 μ M of blebbistatin for 1 h (second and fourth row) to inhibit myosin II
734 contractibility. Scale bar length is 10 μ m.

735

736 **Figure 4.** The VBD domain (TarP⁹⁰⁵⁻¹⁰⁰⁶) of TarP is required for its specific focal adhesion
737 localization. (A) Representation of *C. trachomatis* effector protein TarP and its known domains
738 fused to mTurquoise2 fluorescent protein. (B) Cos7 cells were transfected with different
739 mTurquoise2-tagged TarP constructs (green) and evaluated for effects on focal adhesion numbers
740 (paxillin in red). Phalloidin was used to stain F-actin (blue). Cells were transfected for 20 h at the
741 time of fixation. Scale bar length 10 μ m. (C) Focal adhesion numbers of cells transfected with the
742 different TarP constructs were quantified and are represented as a box-and-whiskers plot. Whiskers

743 represent the lowest and highest data point still within 1.5 times the interquartile range. The light
744 blue asterisks indicate significance relative to the N1-mturquoise2 empty vector control (Wilcoxon
745 rank sum test $***=p<0.001$). Constructs which were statistically different from the empty-vector
746 control were also compared with TarP^{1-1006Δ625-650}, indicated by the dark blue asterisks (Wilcoxon
747 rank sum test $*** = p<0.001$). The black cross shows the average for each experimental sample.

748

749 **Figure 5.** The VBD domain (TarP⁹⁰⁵⁻¹⁰⁰⁶) of TarP is required for focal adhesion resistance to
750 blebbistatin treatment. (A) Cos7 cells were transfected with different mturquoise2-tagged TarP
751 constructs (green) and evaluated for effects on focal adhesion numbers (paxillin in red). Phalloidin
752 was used to stain F-actin (blue). Cos7 cells were transfected for 19 h and then treated with 10 μM
753 of blebbistatin for 1 hr. Scale bar length 10μm. (B, C) NIH3T3 cells were cotransfected with different
754 different mturquoise2-tagged TarP constructs and mcherry-tagged paxillin, and monitored between
755 20 to 22 h post-transfection for 90 min. See Figure S3D and Movies S5-S10 for example images of
756 NIH3T3 cotransfected cells. Box-and-whiskers plot was used to represent recruitment (B) and
757 turnover (C) of paxillin-mcherry FAs in cotransfected cells. Whiskers represent the lowest and
758 highest data point still within 1.5 times the interquartile range. The light blue asterisks indicate
759 significance relative to the N1-mturquoise2 empty vector control (Wilcoxon rank sum test
760 $***=p<0.001$). The black cross shows the average for each experimental sample.

761

762 **Figure 6.** Vinculin is required for *C. trachomatis* L2 and TarP-induced resistance to blebbistatin.
763 MEFs *vcl*^{+/+} (A) and *vcl*^{-/-} (B) cells were mock-infected (top panels) or infected with CtrlL2 for 8 h
764 (bottom panels). White asterisk mark CtrlL2-infected cells. Cells were fixed and stained for the focal
765 adhesion marker paxillin (in green), F-actin (in red) and human serum for *C. trachomatis* (white).
766 MEFs *vcl*^{+/+} (C) and *vcl*^{-/-} (D) cells were transfected with N1-mturquoise2 or TarP⁹⁰⁵⁻¹⁰⁰⁶ (VBD
767 domain) (see Figure S4 for remaining TarP constructs). Cells were fixed and stained for the focal
768 adhesion marker paxillin (in red) and F-actin (in blue). (A-D) Cells were mock-treated (first and third
769 row) or treated with 10μM of blebbistatin for 1 h (second and fourth row) to inhibit myosin II

770 contractibility. Cells without blebbistatin treatment showed clear F-actin stress fibres and paxillin-
771 labeled focal adhesions. Scale bar length is 10 μ m.



772


773 **Figure 7.** Chlamydia alters the nanoscale architecture of focal adhesions. Cos7 cells transfected
774 with paxillin-tdEos (A, B), FAK-tdEos (C, D) and vinculin (E, F) using electroporation, and seeded
775 on gold fiducial coverslip. (A-F) Top panel shows the top view of area around the example focal
776 adhesion (white boxes). Middle panels display a top view of the example focal adhesion. Bottom
777 panel shows the side view and corresponding z histograms. Ctrl2-infected samples display altered
778 vertical (z) organization for paxillin and FAK proteins. The artificial colors are z coordinates for a
779 particular protein in comparison with the fiducial markers (z=0nm, red). Red scale bar length 1 μ m.
780 see Figure S5 for DIC image of the corresponding cells. White scale bar length 200nm.


781

782 **Figure 8.** TarP-targeted focal adhesions display altered nanoscale architecture. Cos7 cells were
783 cotransfected with TarP^{1-1006 Δ 625-650} and paxillin-tdEos (A, B), TarP⁹⁰⁵⁻¹⁰⁰⁶ and paxillin-tdEos (D, E),
784 or with TarP1-829 Δ ^{PRD} and paxillin-tdEos (F) using electroporation, and seed on gold fiducial
785 coverslip. (A-F) Top panel shows the top view of area around the example focal adhesion (white
786 boxes). Middle panels display a top view of the example focal adhesion. Bottom panel shows the
787 side view and corresponding z histograms. Cells transfected with *Chlamydia* effector TarP variants
788 that possess the LDVBD domains (TarP^{1-1006 Δ 625-650} and TarP⁹⁰⁵⁻¹⁰⁰⁶) display altered vertical (z)
789 organization. The artificial colors are z coordinates for a particular protein in comparison with the
790 fiducial markers (z=0nm, red). Red scale bar length 1 μ m. see Figure S5 for DIC image of the
791 corresponding cells. White scale bar length 200nm.


792








A



B



C

